New at CADTH — March 2018

Drug Reimbursement Recommendations

CADTH Common Drug Review

• Nitisinone (Orfadin): Hereditary tyrosinemia type 1
• Guselkumab (Tremfya): Psoriasis, moderate-to-severe plaque
• Infliximab (Renflexis): rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis

CADTH pan-Canadian Oncology Drug Review (pCODR)

• Fulvestrant (Faslodex): Locally Advanced or Metastatic Breast Cancer

CDR Update 133 and pCODR Update 63: CADTH is pleased to announce operational changes that will enhance our Common Drug Review and pan-Canadian Oncology Drug Review programs. These changes reflect our careful consideration of stakeholder feedback and input from the participating jurisdictions.

CDR Update 134: Effective April 2, 2018, CADTH will accept CDR submissions up to six months (180 days) before the anticipated receipt of Health Canada’s Notice of Compliance or Notice of Compliance with Conditions.

Cancer Drug Pipeline Information
The Cancer Drug Pipeline Information for Patient Groups is updated each month.

CADTH Resources

Read the latest “Evidence Matters” column in Hospital News: “Special focus: Innovations in wound care. The pressure’s on: Seeking better options for bed sore prevention.”

Resources to Address the Opioid Crisis
Environmental Scan: Emerging Non-Opioid Drugs for the Treatment of Pain

Issue in Emerging Health Technologies Issue 167 — Monoclonal Antibodies to Prevent Migraine Headaches

CADTH is conducting an Environmental Scan on the current context of non-pharmacological treatment of pain in Canada to better understand the related challenges and opportunities. This scan also supports broader CADTH Opioid Working Group strategies and is being led by CADTH in collaboration with researchers from the Canadian Institutes of Health Research (CIHR) – Strategy for Patient-Oriented Research (SPOR) Chronic Pain Network.

A survey has been developed for this Environmental Scan and targets organizations, service providers, clinical experts, and other stakeholders involved in the care of patients with chronic pain. We expect the survey will be available on the CADTH website later this month. If you would be willing to complete the survey, please email Janice Mann at [email protected]. Stay tuned to our website for more information.

CADTH is committed to helping with the dissemination and uptake of new CIHR Canadian Research Initiative in Substance Misuse (CRISM) Guidelines for the treatment of Opioid Use Disorder. Read more about CRISM.

Health Technology Management Products

Rapid Response
Reports completed in February.

Recent Summaries of Evidence With Critical Appraisals Include:

• Airway Pressure Release Ventilation for Acute Respiratory Distress Syndrome: Clinical Effectiveness and Guidelines
• Clonidine for the Treatment of Psychiatric Conditions and Symptoms: A Review of Clinical Effectiveness, Safety, and Guidelines
• Alpha2-Adrenergic Agonists for the Reduction or Discontinuation of Opioids or Opioid Substitution Therapy: A Review of Clinical Effectiveness and Guidelines

Issues in Emerging Health Technologies

Issue 166 — Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?

Issue 167 — Monoclonal Antibodies to Prevent Migraine Headaches

Optimal Use

Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism

News and Events

Heather Logan appointed CADTH Vice-President of Pharmaceutical Reviews (acting)
CADTH is pleased to announce the appointment of Heather Logan as Vice-President of Pharmaceutical Reviews (acting). Heather joined CADTH earlier this year as Senior Advisor, Pharmaceutical Reviews. Read more.

2018 CADTH Symposium
Registration is now open for our 2018 Symposium, which will be held in Halifax from April 15 to 17, 2018.

Our preliminary program is now available. Check out the list of workshops, presenters, and plenary speakers.

Travel and Hotels: Register and save with special rates on travel and hotel rooms until March 16.

We regularly update information and make announcements about special dates on our website. Be the first to know what’s new by subscribing to our Symposium newsletter.

Evidence-to-Action Event Live from Symposium: Canadian Medical Imaging Inventory
We invite you to attend the launch event of the 2017 Canadian Medical Imaging Inventory (CMII), which provides the latest facts about the location, prevalence, and use of medical imaging equipment across Canada. The launch will be held during the 2018 CADTH Symposium in Halifax on April 16, 2018, from 3:15 p.m. to 4:30 p.m. AT. It will also be broadcast for free via live stream across the country, and all are welcome to sign up. We do request that you register. To attend the event in person you must be a CADTH Symposium delegate or an invited guest.

HTAi 2018 Vancouver
We are pleased to be co-hosting the HTAi 2018 Annual Meeting in Vancouver from June 1 to 5, 2018.

Beyond CADTH

ECRI Institute's 2018 Top 10 Patient Safety Concerns for Healthcare Organizations

Tell Us What You Think

We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please get in touch with your CADTH Liaison Officer.

CADTH E-Alerts: Subscribe to receive the latest CADTH news, reports, feedback opportunities, and events.